Syk-IN-4 is a potent, selective, and orally bioavailable inhibitor of SYK, demonstrating an IC50 of 0.31 nM. It targets SYK, which has been identified as a potential therapeutic target for autoimmunity and hematological cancers[1].
* VAT and and shipping costs not included. Errors and price changes excepted